CCR2 and neoplasm: Importantly, this impact on CD8+ T cell numbers appears to be restricted to the tumor, as depletion of monocytes by anti-CCR2 treatment did not impact blood CD8+ T cell frequencies following either first or second dose of OVT (Supplementary Fig. 5g).